title: Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
authors.affiliation: Maple Leaf Medical Clinic, Toronto, Canada.
authors.forename: Mona
authors.initials: M
authors.lastname: Loutfy
authors.forename: Esteban
authors.initials: E
authors.lastname: Ribera
authors.forename: Eric
authors.initials: E
authors.lastname: Florence
authors.forename: Stéphane
authors.initials: S
authors.lastname: De Wit
authors.forename: Antonella
authors.initials: A
authors.lastname: Castagna
authors.forename: Robert
authors.initials: R
authors.lastname: Ryan
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Hilde
authors.initials: H
authors.lastname: Vanaken
authors.forename: Yvonne
authors.initials: Y
authors.lastname: van Delft
authors.forename: Stephan
authors.initials: S
authors.lastname: Marks
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010446:Peptide Fragments / Q000627:therapeutic use*; D010865:Pilot Projects; D011724:Pyridazines / Q000627:therapeutic use*; D011743:Pyrimidines; D012367:RNA, Viral / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D009570:Nitriles; D010446:Peptide Fragments; D011724:Pyridazines; D011743:Pyrimidines; D012367:RNA, Viral; C451734:etravirine; D000077560:Enfuvirtide